


Study 5 (réf. 89-90-1) :

## PERENNIAL ALLERGIC RHINITIS DUE TO AEROALLERGENS

**Study type:** Double-blind multi-centre study: ESOC (standardised quail's egg extract) versus placebo. Monotherapy.  
**Aims:** To evaluate the efficacy and safety of ESOC compared to placebo in adult subjects with perennial allergic rhinitis.

**Authors:** Dr. M. Hantzperg, Coordinator  
**Centres:** 33 centres participated in the study  
**Study period:** May 1989 – February 1990  
**Methodology:** Five evaluations by the doctor and the patient of symptoms, efficacy and tolerance.  
Treatment duration: 42 days  
**Number of patients:** 124 patients:  
ESOC: 63 adults (34.6 +/- 11.2)  
placebo: 61 adults (35.3 +/- 14.1)



**Efficacy:** Doctor's assessment: There was a significant difference in the number of successes in the ESOC group (63.4%) compared to the number of successes in the placebo group (27.3%).  
Patient's assessment: There was a significant difference in the number of successes in the ESOC group (65.7%) compared to the number of successes in the placebo group (25%).

**Conclusion:** This clinical study demonstrates the efficacy of sublingual ESOC for the treatment of perennial rhinitis symptoms (rhinorrhoea, sneezing, blocked nose, watery eyes and conjunctivitis) due to aeroallergens such as dust mites, feathers and animal hair, in a population of adolescents and young adults. This study also confirms that the product is well tolerated.